In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biopharma Dealmaking Quarterly Statistics, Q1 2013

A look at the financing, M&A, and alliance activity January-March 2013

Executive Summary

Biopharma financing reached $4.6 billion in Q1 2013, exceeding Q4 2012’s $4.2 billion total, mostly through follow-on public offerings, which made up 47% of the total funding. Conversely, M&A was on the decline with 18 completed transactions together valued at $4.8 billion, the lowest quarter since 2009. The $5.5 billion potential deal value aggregate for alliances more than doubled from the previous quarter, mainly due to Biogen Idec’s $3.25 billion buy of Elan's share of multiple sclerosis drug Tysabri.

You may also be interested in...



AZ’s Make Or Break Moment Comes Down To Business Development

AstraZeneca needs new assets to change investors’ dismal outlook for the company. With a new CEO installed, an R&D shakeup underway, and a new portfolio strategist joining in May, AstraZeneca will embark on an ambitious acquisition and partnering strategy in 2013.

Is Brilinta The Treatment To Keep AstraZeneca’s Lifeblood Flowing?

The company outlined plans to jumpstart growth of the anti-platelet drug Brilinta, including a 100% increase in marketing investment, increased rebates for payers and the addition of 200 nurse educators who will focus on the hospital discharge space.

J&J Gains FDA OK For First-In-Class Type 2 Diabetes Drug Invokana

J&J is the first pharma company to bring an SGLT2 inhibitor to market, but its window of exclusivity in that class may be narrow, given that FDA is slated to assess two other SGLT2s later this year.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1123738

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel